

BBTS Annual
Conference 2016

Do Pathogen Inactivation Systems Offer an Alternative to Platelet Screening?

Jennifer Allen

Biomedical Scientist Team Leader

National Bacteriology Laboratory, NHSBT Colindale



Overview

- Bacterial Risk to Platelets
- Screening and affect on safety
- PI principles
- Our study
- Outcomes
- Further work


Bacterial Risk to Platelets

- Platelets at high risk from contamination
- Storage at 22°C
 - maintains platelet viability and function
- UK SHOT reports 1996 - 2010
 - 36 transmissions from platelets
 - 9 deaths (81.8%)
- USA FDA 2005-2013
 - 28 of 32 (87.5%) fatalities



Image: Platelet unit contaminated with *Staphylococcus aureus*

Confirmed TTI Due to Contaminated Platelets



Bacterial Screening Provides A Very Safe System

- Over 1.4 million donations screened to date
- 1 confirmed and 1 “possible” transmission
- 4 near-misses
 - 3 *Staphylococcus aureus*, 1 *Serratia marcescens*
- False negative rate of 0.0003%


Pathogen Inactivation Systems Assessed as an Alternative to Screening for Platelet Components

Cerus Intercept and TerumoBCT Mirasol systems


Pathogen Inactivation

- Treatment of a range of products
 - Platelets and plasma treatment systems commercially available
 - Treatment of red cells and whole blood also in development

- Targets RNA and DNA in the sample
 - Inactivates white cells
 - Prevents bacterial replication
 - Platelets, red cells and plasma unaffected



Cerus Intercept Mechanism of Action



TerumoBCT- Mirasol System for Platelet Components



NBL Evaluation Method

- Day 1 buffy coat pooled platelets in SSP+ (additive solution)
- Concentrations assessed:
 - 10^{-1} CFU/ml
 - 10^3 CFU/ml
 - 10^4 CFU/ml
 - 10^5 CFU/ml
- Concentrations cover range of growth possible at time of treatment
- 3 units per concentration
 - 2 treated “test” units, 1 untreated control

NBL Evaluation Method


- Pool and split
- Bags spiked with bacteria and enumerated
- Stored in a platelet shaker for two hours (22°C)
- Sampled (enumerated/BacT/ALERT) and treated
- Sampled immediately post treatment (enumerated/ BacT/ALERT)
- Stored in a platelet shaker for the remaining shelf life (up to 7 days)
- At day 7, enumerated/BacT/ALERT

Organisms assessed


- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Listeria monocytogenes*
- *Serratia marcescens*
- *Staphylococcus aureus*
- *Staphylococcus epidermidis*
- *Streptococcus bovis*
- *Streptococcus dysgalactiae*
- *Streptococcus oralis*
- *Streptococcus pneumoniae*
- *Pseudomonas aeruginosa* (Intercept only)
- *Bacillus cereus* (Intercept only)

Cerus Intercept Results


Effect of Intercept Treatment on Bacterial Growth in Units Inoculated to Achieve 10⁻¹ CFU/ml




Effect of Intercept Treatment on Bacterial Growth in Units Inoculated to Achieve 10³ CFU/ml



Effect of Intercept Treatment on Bacterial Growth in Units Inoculated to Achieve 10⁵ CFU/ml




Effect of Intercept Treatment on Growth of *Serratia marcescens* in Units Inoculated with 10^3 , 10^4 and 10^5 CFU/ml




*Enrichment culture (BacT/ALERT) detected at 10^5 cfu/ml in one replicate of repeat 1 and 2.

Effects of Cerus Intercept Treatment on Growth of *Pseudomonas aeruginosa* in Units Inoculated with 10^3 , 10^4 and 10^5 CFU/ml




TerumoBCT Mirasol Results


Effects of Mirasol Treatment on Bacterial Growth in Units Inoculated to Achieve 10^{-1} CFU/ml




Effects of Mirasol Treatment on Bacterial Growth in Units Spiked to Achieve 10³ CFU/ml



Effects of Mirasol Treatment on Bacterial Growth in Units Spiked to Achieve 10⁴ CFU/ml



Effects of Mirasol Treatment on Bacterial Growth in Units Spiked to Achieve 10^5 CFU/ml



Conclusion

- All organisms inactivated at low concentrations
- Treatment most appropriate nearer to the point of donation
- Log reduction data is misleading
- Terminal sterility needs to be gold standard for system validation

Future PI Studies

- Assess effect of range of treatment times within guidelines
 - Ensure maximal effectiveness for NHSBT
 - Consideration of current logistics limits
- Breakpoint concentrations
 - Provide assurance as to capabilities of system
- Evaluation of treatment of platelets in 100% plasma

Bacterial Screening or PI will not be perfect

Both, if used appropriately, will significantly reduce morbidity and mortality in patients

Acknowledgments

Carl McDonald

Kate Aplin

Joanne Ball

Gabrielle Orr

Cristina Santos

Danuta Sawicka

Richard de Ritis

THANK YOU

jennifer.allen@nhsbt.nhs.uk